| Theme | Intestinal malignant lymphoma | |
|---|---|---|
| Title | Burkitt lymphoma -- diagnosis and therapy | |
| Publish Date | 2015/05 | |
| Author | Ichiro Moriyama | Department of Hematology and Oncology, Shimane University Cancer Center |
| Author | Junji Suzumiya | Department of Hematology and Oncology, Shimane University Cancer Center |
| Author | Tsutomu Takahashi | Department of Hematology and Oncology, Shimane University Cancer Center |
| Author | Satoshi Kumanomido | Department of Hematology and Oncology, Shimane University Cancer Center |
| Author | Fumiyoshi Ikejiri | Department of Hematology and Oncology, Shimane University Cancer Center |
| Author | Koushi Kawakami | Department of Hematology and Oncology, Shimane University Cancer Center |
| Author | Masaya Inoue | Department of Hematology and Oncology, Shimane University Cancer Center |
| Author | Takaaki Miyake | Department of Hematology and Oncology, Shimane University Cancer Center |
| Author | Hironobu Mikami | Department of Gastroenterology and Hepatology, Shimane University School of Medicine |
| [ Summary ] | Burkitt lymphoma is a highly aggressive B-cell lymphoma, and usually presents with an abdominal mass or involvement of other extra-nodal sites. The abdominal mass can cause abdominal pain, vomiting, gastrointestinal bleeding, and intussusception. Some patients show bone marrow and central nervous system (CNS) involvement. The diagnosis of Burkitt lymphoma is based upon the clinical features, histology, immunohistochemical findings, such as percentage of Ki-67 (MIB-1) positive cells approaching 100 %, no expression of BCL-2 and rearrangements involving the MYC gene. The standard treatment for Burkitt lymphoma is intensive multi-agent therapy such as CODOX-M/IVAC and hyper-CVAD with CNS prophylaxis. Addition of rituximab to intensive chemotherapy can be effective in Burkitt lymphoma. Here, we report the cases of two patients aff ected by Burkitt lymphoma with gastrointestinal lesions. | |